Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corina Dota

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
British Journal of Clinical Pharmacology|December 12, 2022
Verinurad does not prolong QTc interval: a thorough QT study using concentration-QTc modellingJoanna Parkinson, Corina Dota, Christian Källgren, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|September 15, 2017
An Analysis of the Relationship Between Preclinical and Clinical QT Interval-Related DataChristopher E Pollard, Matthew Skinner, Stanley E Lazic, et al.
British Journal of Clinical Pharmacology|July 26, 2021
Concentration-QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrationsVeronika Voronova, Marie Cullberg, Philip Delff, et al.
British Journal of Clinical Pharmacology|June 2, 2022
AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT intervalDinko Rekić, Ivan Azarov, Jane Knöchel, et al.
British Journal of Clinical Pharmacology|August 20, 2021
Concentration-QT modelling in early clinical oncology settings: Simulation evaluation of performanceGael Cantet, Alienor Berges, Rhianna O'Sullivan, et al.
Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc|December 31, 2013
The IQ-CSRC prospective clinical Phase 1 study: "Can early QT assessment using exposure response analysis replace the thorough QT study?"Borje Darpo, Nenad Sarapa, Christine Garnett, et al.
Journal of Clinical Pharmacology|August 6, 2019
Evaluation of the Effect of 5 QT-Positive Drugs on the JTpeak Interval - An Analysis of ECGs From the IQ-CSRC StudyBorje Darpo, Charles Benson, Randy Brown, et al.
Cancer Chemotherapy and Pharmacology|June 27, 2023
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label studyMats Någård, Mei-Lin Ah-See, James Strauss, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry PerspectiveHugo M Vargas, Michael G Rolf, Todd A Wisialowski, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
British Journal of Clinical Pharmacology|December 12, 2022
Verinurad does not prolong QTc interval: a thorough QT study using concentration-QTc modellingJoanna Parkinson, Corina Dota, Christian Källgren, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|September 15, 2017
An Analysis of the Relationship Between Preclinical and Clinical QT Interval-Related DataChristopher E Pollard, Matthew Skinner, Stanley E Lazic, et al.
British Journal of Clinical Pharmacology|July 26, 2021
Concentration-QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrationsVeronika Voronova, Marie Cullberg, Philip Delff, et al.
British Journal of Clinical Pharmacology|June 2, 2022
AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT intervalDinko Rekić, Ivan Azarov, Jane Knöchel, et al.
British Journal of Clinical Pharmacology|August 20, 2021
Concentration-QT modelling in early clinical oncology settings: Simulation evaluation of performanceGael Cantet, Alienor Berges, Rhianna O'Sullivan, et al.
Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc|December 31, 2013
The IQ-CSRC prospective clinical Phase 1 study: "Can early QT assessment using exposure response analysis replace the thorough QT study?"Borje Darpo, Nenad Sarapa, Christine Garnett, et al.
Journal of Clinical Pharmacology|August 6, 2019
Evaluation of the Effect of 5 QT-Positive Drugs on the JTpeak Interval - An Analysis of ECGs From the IQ-CSRC StudyBorje Darpo, Charles Benson, Randy Brown, et al.
Cancer Chemotherapy and Pharmacology|June 27, 2023
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label studyMats Någård, Mei-Lin Ah-See, James Strauss, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry PerspectiveHugo M Vargas, Michael G Rolf, Todd A Wisialowski, et al.
Pageof 2